Browse studies

Find your next paid study

54 recruiting studies matching your filters

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis

The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia …

Myasthenia Gravis, Generalized

Estimated

~$10 – $8,750

Vertex Pharmaceuticals IncorporatedNCT07501702

Phase 2

A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Generalized Myasthenia Gravis (gMG)

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric particip…

Generalized Myasthenia Gravis

Zilucoplan Treatment of Severe MG Exacerbations Leading to Hospitalization of Participants With Acetylcholine Receptor Antibody Positive gMG

This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients…

Generalized Myasthenia Gravis (gMG)

Estimated

~$10 – $7,500

Miriam FreimerNCT07215949

Phase 2

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis

This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with M…

Myasthenia GravisMyasthenia Gravis, MuSK

Estimated

~$10 – $8,750

NMD Pharma A/SNCT06414954

AXIS Autoimmune Neurology Registry

The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with mya…

Myasthenia Gravis (MG)Myasthenia Gravis, GeneralizedMyasthenia Gravis, Ocular+12 more

Estimated

~$10 – $1,125

Autoimmune Neurology AllianceNCT07761026

Phase 1

A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases

This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its saf…

Chronic Inflammatory Demyelinating PolyneuropathyMyasthenia GravisMultiple Sclerosis

Estimated

~$10 – $7,500

Kite, A Gilead CompanyNCT07304154

Phase 1

RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis

RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis

Generalized Myasthenia Gravis (gMG)

Estimated

~$10 – $7,500

Cabaletta BioNCT06359041

Remote eligible

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA): Pregnancy Registry for Women With Chronic Conditions

PRISMA, is a pregnancy registry study, focused on comprehensively collecting information about pregnancy in women with chronic neurological conditions from acr…

Multiple SclerosisClinically Isolated SyndromeNMOSD+1 more

Estimated

~$10 – $675

University of California, San FranciscoNCT06940323

Genome Wide Association Study of Patients With Muscle Specific Kinase Myasthenia Gravis

The MuSK myasthenia gravis 1000 study seeks to collect saliva samples from 1000 subjects with laboratory confirmed diagnosis of MuSK myasthenia to identify gen…

Myasthenia GravisMuSK MGMuSK Myasthenia Gravis

Estimated

~$10 – $750

George Washington UniversityNCT06259071

Phase 1

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis

This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effec…

Myasthenia Gravis, Generalized

Estimated

~$10 – $8,750

Aurinia Pharmaceuticals Inc.NCT07596901

Phase 2

An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 year…

Myasthenia Gravis

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT05265273

Phase 3

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis

The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravi…

Generalized Myasthenia Gravis

Estimated

~$10 – $8,750

Immunovant Sciences GmbHNCT07039916